FTC Slams Amgen's Antitrust Shield Argument At 4th Circ.
The Federal Trade Commission has urged the Fourth Circuit to reject Amgen's "sweeping" assertion that commercial agreements for acquiring the rights to patent applications are shielded from antitrust scrutiny, saying the...To view the full article, register now.
Already a subscriber? Click here to view full article